Efficacy, Pharmacodynamics, and Pharmacokinetics of CGP 51901, AnAnti-Immunoglobulin E Chimeric Monoclonal Antibody, in Patients withSeasonal Allergic Rhinitis

@article{Kamada1999EfficacyPA,
  title={Efficacy, Pharmacodynamics, and Pharmacokinetics of CGP 51901, AnAnti-Immunoglobulin E Chimeric Monoclonal Antibody, in Patients withSeasonal Allergic Rhinitis},
  author={A. Kamada},
  journal={Pediatrics},
  year={1999},
  volume={104},
  pages={370-371}
}
1. Racine-Poon A, 2. Botta L, 3. Chang TW, 4. et al. (1997) Clin Pharmacol Ther. 62:675–690. [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] #### Purpose of the Study A dose-ranging study was performed to evaluate the safety and efficacy, and pharmacodynamics and pharmacokinetics of CGP 51901, a recombinant monoclonal mouse-human chimeric anti-human immunoglobulin-E (IgE) antibody, in adults with allergic rhinitis. This model was chosen because the cause-effect relationship of… Expand